Identification of MXRA5 as a novel biomarker in colorectal cancer

Wang,Guang-Hui; Yao,Ling; Xu,Hong-Wei; Tang,Wen-Tao; Fu,Ji‑Hong; Hu,Xiao-Fang; Cui,Long; Xu,Xue-Min

doi:10.3892/ol.2012.1038

Identification of MXRA5 as a novel biomarker in colorectal cancer

Authors:
- Guang-Hui Wang
- Ling Yao
- Hong-Wei Xu
- Wen-Tao Tang
- Ji‑Hong Fu
- Xiao-Fang Hu
- Long Cui
- Xue-Min Xu
View Affiliations

Affiliations: Colorectal Surgery Department, Xinhua Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200092, P.R. China, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai 200092, P.R. China, Department of Gastroenterology, Kunshan Hospital of Traditional Chinese Medicine, Jiangsu 215300, P.R. China, School of Biomedical Engineering and Med-X Research Institute, Shanghai Jiao Tong University, Shanghai 200092, P.R. China
Published online on: November 21, 2012 https://doi.org/10.3892/ol.2012.1038
Pages: 544-548

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

In our previous study, significantly high expression levels of matrix-remodeling associated 5 (MXRA5) were identified in fresh-cultured colorectal cancer (CRC) tissues compared with their normal adjacent mucosa by differential secretome analysis. Whether MXRA5 is a potential serum biomarker of CRC has not been evaluated. The aim of this study was to investigate the association between MXRA5 expression and clinicopathological characteristics of CRC patients. The MXRA5 expression levels were determined by quantitative real-time PCR (qRT‑PCR) and immunohistochemistry (IHC) in 20 colorectal adenoma tissues, 156 CRC tissues and their corresponding adjacent normal mucosa. Relative quantity (RQ) value and immunoreactive score (IRS) were used for quantitative assessment. The staining for MXRA5 protein was mainly located in the cytoplasm of CRC cells. All CRC tissues were positively stained, with a higher expression rate (IRS>4) of 67% (105/156), and a lower expression rate (IRS≤4) of 33% (51/156). Meanwhile, their corresponding normal tissues exhibited little positive staining; the higher expression rate was 0% (0/156) and the lower expression rate was 25% (16/156). Additionally, more than half of the adenoma tissues were positively stained; the higher expression rate was 15% (3/20) and the lower expression rate was 50% (10/20). The MXRA5 protein positive staining rates were significantly correlated with the lesion sites (colon vs. rectum, 76 vs. 59%), TNM staging (I+II vs. III+IV, 56 vs. 73%) and metastasis (present vs. absent; 76 vs. 61%) with the most high positive staining rate observable in omental metastasis (82%). However, MXRA5 mRNA expression levels showed no significant differences between CRC tissues and their corresponding normal tissues, and no significant correlation between IRS and corresponding RQ value was observed. In this study, we present the first evaluation of MXRA5 protein expression in CRC tissue. Our results revealed that MXRA5 protein is aberrantly expressed in CRC tissues, and has potential value in early detection of CRC and prediction of omental metastasis.

View Figures

View References

1.	Siegel R, Ward E, Brawley O and Jemal A: Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 61:212–236. 2011. View Article : Google Scholar : PubMed/NCBI
2.	Ross JS: Biomarker update for breast, colorectal and non-small cell lung cancer. Drug News Perspect. 23:82–88. 2010. View Article : Google Scholar : PubMed/NCBI
3.	Bast RC Jr, Ravdin P, Hayes DF, et al: 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 19:1865–1878. 2001.PubMed/NCBI
4.	Duffy M, Van Dalen A, Haglund C, et al: Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. Eur J Cancer. 43:1348–1360. 2007. View Article : Google Scholar : PubMed/NCBI
5.	Wang Q, Zhang YN, Lin GL, et al: S100P, a potential novel prognostic marker in colorectal cancer. Oncol Rep. 28:303–310. 2012.
6.	Higashijima J, Kurita N, Miyatani T, et al: Expression of histone deacetylase 1 and metastasis-associated protein 1 as prognostic factors in colon cancer. Oncol Rep. 26:343–348. 2011.PubMed/NCBI
7.	Walther A, Johnstone E, Swanton C, Midgley R, Tomlinson I and Kerr D: Genetic prognostic and predictive markers in colorectal cancer. Nat Rev Cancer. 9:489–499. 2009. View Article : Google Scholar : PubMed/NCBI
8.	Siena S, Sartore-Bianchi A, Di Nicolantonio F, Balfour J and Bardelli A: Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J Natl Cancer Inst. 101:1308–1324. 2009. View Article : Google Scholar : PubMed/NCBI
9.	Helgason HH, Engwegen JY, Zapatka M, et al: Identification of serum proteins as prognostic and predictive markers of colorectal cancer using surface enhanced laser desorption ionization-time of flight mass spectrometry. Oncol Rep. 24:57–64. 2010. View Article : Google Scholar
10.	Chung CH, Seeley EH, Roder H, et al: Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients. Cancer Epidemiol Biomarkers Prev. 19:358–365. 2010. View Article : Google Scholar : PubMed/NCBI
11.	Sun W, Xing B, Sun Y, et al: Proteome analysis of hepatocellular carcinoma by two-dimensional difference gel electrophoresis: novel protein markers in hepatocellular carcinoma tissues. Mol Cell Proteomics. 6:1798–1808. 2007. View Article : Google Scholar
12.	Phizicky E, Bastiaens PI, Zhu H, Snyder M and Fields S: Protein analysis on a proteomic scale. Nature. 422:208–215. 2003. View Article : Google Scholar : PubMed/NCBI
13.	Yao L, Lao W, Zhang Y, et al: Identification of EFEMP2 as a serum biomarker for the early detection of colorectal cancer with lectin affinity capture assisted secretome analysis of cultured fresh tissues. J Proteome Res. Apr 30–2012.(Epub ahead of print).
14.	Olski TM, Noegel AA and Korenbaum E: Parvin, a 42 kDa focal adhesion protein, related to the alpha-actinin superfamily. J Cell Sci. 114:525–538. 2001.PubMed/NCBI
15.	Lozada C, Levin RI, Huie M, et al: Identification of C1q as the heat-labile serum cofactor required for immune complexes to stimulate endothelial expression of the adhesion molecules E-selectin and intercellular and vascular cell adhesion molecules 1. Proc Natl Acad Sci USA. 92:8378–8382. 1995. View Article : Google Scholar
16.	Walker MG and Volkmuth W: Cell adhesion and matrix remodeling genes identified by co-expression analysis. Gene Function & Disease. 3:109–112. 2002.
17.	Alsner J, Rødningen OK and Overgaard J: Differential gene expression before and after ionizing radiation of subcutaneous fibroblasts identifies breast cancer patients resistant to radiation-induced fibrosis. Radiother Oncol. 83:261–266. 2007. View Article : Google Scholar
18.	Rødningen OK, Børresen-Dale AL, Alsner J, Hastie T and Overgaard J: Radiation-induced gene expression in human subcutaneous fibroblasts is predictive of radiation-induced fibrosis. Radiother Oncol. 86:314–320. 2008.PubMed/NCBI
19.	Chondrogianni N, de C M Simoes D, Franceschi C and Gonos ES: Cloning of differentially expressed genes in skin fibroblasts from centenarians. Biogerontology. 5:401–409. 2004. View Article : Google Scholar : PubMed/NCBI
20.	Buckanovich RJ, Sasaroli D, O’Brien-Jenkins A, et al: Tumor vascular proteins as biomarkers in ovarian cancer. J Clin Oncol. 25:852–861. 2007. View Article : Google Scholar : PubMed/NCBI
21.	Zou TT, Selaru FM, Xu Y, et al: Application of cDNA microarrays to generate a molecular taxonomy capable of distinguishing between colon cancer and normal colon. Oncogene. 21:4855–4862. 2002. View Article : Google Scholar : PubMed/NCBI
22.	Sompayrac SW, Mindelzun RE, Silverman PM and Sze R: The greater omentum. AJR Am J Roentgenol. 168:683–687. 1997. View Article : Google Scholar : PubMed/NCBI
23.	Kehinde E, Abdeen S, Al-Hunayan A and Ali Y: Prostate cancer metastatic to the omentum. Scand J Urol Nephrol. 36:225–227. 2002. View Article : Google Scholar : PubMed/NCBI
24.	Chou CK, Liu GC, Su JH, Chen LT, Sheu RS and Jaw TS: MRI demonstration of peritoneal implants. Abdom Imaging. 19:95–101. 1994. View Article : Google Scholar : PubMed/NCBI
25.	Levitt RG, Koehler RE, Sagel SS and Lee JK: Metastatic disease of the mesentery and omentum. Radiol Clin North Am. 20:501–510. 1982.PubMed/NCBI
26.	Silverman P and Cooper C: Mesenteric and omental lesions. Textbook of Gastrointestinal Radiology. 1st edition. WB Saunders; Philadelphia, PA: 1994
27.	Fujiwara H, Saga Y, Takahashi K, et al: Omental metastases in clinical stage I endometrioid adenocarcinoma. Int J Gynecol Cancer. 18:165–167. 2008. View Article : Google Scholar : PubMed/NCBI